Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ccr.2022.214899
DC FieldValue
dc.titleTargeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II
dc.contributor.authorArakelyan, J
dc.contributor.authorRusanov, DA
dc.contributor.authorChang, MR
dc.contributor.authorAsaturova, AV
dc.contributor.authorKireeva, GS
dc.contributor.authorAlshehri, M
dc.contributor.authorAng, WH
dc.contributor.authorBabak, MV
dc.date.accessioned2023-01-11T01:35:28Z
dc.date.available2023-01-11T01:35:28Z
dc.date.issued2023-01-15
dc.identifier.citationArakelyan, J, Rusanov, DA, Chang, MR, Asaturova, AV, Kireeva, GS, Alshehri, M, Ang, WH, Babak, MV (2023-01-15). Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II. Coordination Chemistry Reviews 475 : 214899-214899. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ccr.2022.214899
dc.identifier.issn0010-8545
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/236061
dc.description.abstractIn this last decade, our understanding of the complex factors and processes that drive cancer development and progression has broadened in scope and grown in depth. Today, it is widely held that as a disease, cancer can be characterized in terms of specific hallmarks that normal cells need to acquire to transform into malignant cells. Because it is both logical and intuitive, the hallmarks of cancer concept has been adopted by both the scientific and medical community as an organising principle to understand cancer and to develop new therapeutic approaches. Several new hallmarks have emerged in recent years arising from a better understanding of the crosstalk between cancer cells and their surrounding tumor microenvironment. The current review is based on the collaborative efforts of bioinorganic chemists, molecular biologists and medical doctors. It focuses on the use of transition metals as therapeutic drugs to treat malignancies arising from epigenetic dysregulation and compares the therapeutic approaches of transition metal complexes over existing drugs in clinical use.
dc.publisherElsevier BV
dc.sourceElements
dc.typeReview
dc.date.updated2023-01-11T01:10:31Z
dc.contributor.departmentDEAN'S OFFICE (SCIENCE)
dc.description.doi10.1016/j.ccr.2022.214899
dc.description.sourcetitleCoordination Chemistry Reviews
dc.description.volume475
dc.description.page214899-214899
dc.published.stateUnpublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
1-s2.0-S0010854522004945-main.pdfPublished version4.72 MBAdobe PDF

CLOSED

Published

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.